Fulgent Genetics Inc. (NASDAQ: FLGT) stock soared 10.59% in pre-market trading on Friday following the release of its second-quarter 2025 financial results, which exceeded analyst expectations and included an upward revision of the company's full-year guidance.

The genetic testing solutions provider reported an adjusted earnings per share (EPS) of $0.07 for Q2, significantly outperforming the analyst consensus estimate of -$0.18. This impressive beat represents a 138.25% surprise to the upside, although it's worth noting that it's still a 53.33% decrease from the $0.15 per share reported in the same quarter last year. Revenue for the quarter came in at $81.803 million, surpassing the analyst estimate of $76.205 million by 7.35% and marking a 15.17% increase from the $71.028 million reported in the year-ago period.

Adding to the positive sentiment, Fulgent Genetics raised its core revenue guidance for 2025 to $320 million, signaling confidence in its growth trajectory. However, the company also provided an outlook for a full-year non-GAAP loss per share of about $0.35, indicating ongoing challenges despite the revenue growth. The market's strongly positive reaction suggests that investors are focusing on the revenue beat and raised guidance, seeing potential for future profitability as the company continues to grow its core business.